Introduction {#sec1-1}
============

Tamoxifen (TAM) is commonly used as an adjuvant therapy in the antihormonal treatment of choice in premenopausal breast cancer patients. It is a non-steroidal selective estrogen receptor modulator (SERM) and, like clomiphene citrate, it has also been used to induce ovulation. It is also known that Tamoxifen increases the incidence of ovarian follicular cysts.^[@ref1],[@ref2]^ On the other hand, histopathological study of material from prophylactic oophorectomies performed for a genetic predisposition to ovarian cancer can reveal cytological and architectural abnormalities considered to be pre-cancerous manifestations. These abnormalities are termed *dysplasia* by analogy with the pre-invasive lesions described for the genital tract (vulva, vagina, cervix, endometrium).^[@ref3]^ Similarly, serous tubal intraepithelial lesions (STILs, a spectrum of epithelial changes ranging from normal appearing tubal epithelium to lesions with cytologic atypia and dysplasia) have recently been described in prophylactically removed Fallopian tubes of women predisposed to develop ovarian cancer.^[@ref10],[@ref11]^ Moreover, several studies have found similar ovarian dysplasia lesions after stimulation of ovulation in infertile patients.^[@ref12]^ We sought to identify dysplasia lesions in salpingo-oophorectomies associated with Tamoxifen and to assess the expression of proliferation and differentiation-related proteins (Ki67, p53, and Aldehyde dehydrogenase 1 or ALDH1).^[@ref2],[@ref3]^ To the best of our knowledge, this is the first study to assess tubo-ovarian lesions under TAM on the one hand, and on the other to underline the accuracy of ALDH1 staining as for tubo-ovarian precursor lesions.

Materials and Methods {#sec1-2}
=====================

Patients {#sec2-1}
--------

Between January 1995 and December 2000, we selected three groups of patients:

*Group A: salpingo-oophorectomies associated with tamoxifen exposure (TAM group).* We included 42 removed ovaries and tubes associated with tamoxifen exposure for previous breast cancer without BRCA mutation. Two occult ovarian carcinomas were excluded from the dysplasia evaluation study because morphological dysplasia analysis was designed to identify potential premalignant lesions.

*Group B: salpingo-oophorectomies associated with clomiphene citrate.* We selected an infertile population who had adnexectomies after ovulation induction by clomiphene several years later and whose ovaries and tubes were reported as normal on routine histological examination: 15 cases were included.

*Group C: Control group.* We selected a spontaneously non cancerous and fertile population of matching age, with no personal nor family history of gynaecologic neoplasia (breast, ovary, endometrium), who underwent adnexectomy for which the histopathological examination concluded that the ovaries and tubes did not show any sign of cancerous or borderline pathology or salpingitis: 116 controls were included in the study.

Histopathological criteria {#sec2-2}
--------------------------

### Evaluation of morphological features {#sec3-1}

Morphological studies were processed on 3 micron paraffin sections stained with standard haematoxylin phloxin safran (HPS). The number of sections available for review for each case (ovary and tube) ranged from 7 to 11 in all groups.

The histopathology slides for the 40 patients who had used Tamoxifen, 15 patients who had used Clomiphene citrate and the 116 control were all scored blinded by two spcialists in gynecopathology (FPL and IR) who were specialists in onco-gynaecology pathology, in order to obtain an average score. As initialy described in ovarian dysplasia studies,^[@ref12],[@ref13],[@ref15]^ when several slides were available, the one with the highest dysplasia score was retained. For the ovarian cystectomies, the slides were read to confirm the histopathological diagnosis and to inspect associated ovarian tissue to determine its dysplasia score. Absence of associated ovarian tissue was an exclusion criterion. In the event of obvious disagreements between pathologists, a further examination was carried out to reach a consensus.

### Ovarian dysplasia {#sec3-2}

There is no consensual dysplasia scoring system, as the histopathological characteristics of dysplasia are difficult and subtle to determine. The definition of ovarian dysplasia was thus based on cytological and architectural criteria described in previous studies of ovarian dysplasia, *i.e.,* dysplasia found in prophylactic oophorectomy for BRCA mutations,^[@ref3]^ in areas adjacent to Stage 1 ovarian carcinoma,^[@ref6],[@ref7]^ in the contralateral ovary in case of unilateral ovarian cancer,^[@ref8],[@ref9]^ and in relation to ovulation induction.^[@ref12]^ We pooled the criteria to design an eleven criteria (listed below) scoring system used in our previous studies on the relationship between ovarian dysplasia, ovulation induction, and genetic risk:^[@ref13]^

1.  \- epithelial pseudostratification

2.  \- epithelial proliferation : pilling up the cells, increased cellularity and Ki67 expression, as previously published^[@ref13]^

3.  \- surface papillomatosis

4.  \- irregular nuclear chromatine pattern

5.  \- irregular nuclear contour

6.  \- cellular pleiomorphism

7.  \- increase in nuclear size (nuclear-cytoplasmic ratio and comparison to the normal nuclei)

8.  \- inclusion cysts (presence of more than three contiguous cysts)

9.  \- deep epithelial invaginations

10. \- psammoma

11. \- stromal hyperplasia.

In each case, the abnormal areas were scored between 0 and 2 (0, normal; 1, moderately abnormal; 2, severely abnormal), whether located on the surface or in an inclusion cyst. An overall dysplasia ovarian score was then obtained for each patient by simply adding the scores for each of the 11 items (total range: 0 to 22).

### Tubal dysplasia {#sec3-3}

As for the ovary, the difficulty of analysing tubal dysplasia can be explained by the lack of well established morphological criteria for precursors of Fallopian tube carcinoma. Our definition was based on previous studies of tubal precursor lesions (named *Serous Tubal Intraepithelial Lesions*, STILs) described in Fallopian tubes from patients with a genetic risk (prophylactic oophorectomy for BRCA1/2 mutations), and we designed a scoring system with seven histopathological criteria:^[@ref10],[@ref11],[@ref16]^

1.  \- epithelial pseudostratification

2.  \- tufting

3.  \- loss of nuclear polarity

4.  \- increase in nuclear density

5.  \- nuclear atypia

6.  \- nucleomegaly

7.  \- loss of ciliation

In each case, the abnormal areas were scored between 0 and 2 (0, normal; 1, moderately abnormal; 2, severely abnormal). An overall dysplasia tubal score was then obtained for each patient by simply adding the scores for each of the 7 items (total range: 0 to 14).

Evaluation of immunostaining {#sec3-4}
----------------------------

Immunohistochemistry was performed on 3 micron sections, on silanised slides dried overnight at 56°C. Ki67, P53 and ALDH1 immunostaining was performed with a BenchmarkXT immunostainer (Ventana Medical Systems, Illkirch, France) as indicated in [Table 1](#table001){ref-type="table"}. For Ki67 and P53, immunostaining was evaluated semiquantitatively and independently by two pathologists (IR, FPL) using a scoring protocol described in studies of immunohistochemistry and ovarian dysplasia:^[@ref19]^ an immunoreactive score (IRS) ranging from 0 to 12 was defined as the product of staining intensity (0 to 3) and the percentage of cells with nuclear staining (0 to 4). Scores between 0 and 3 were defined as low, scores between 4 and 7 were defined as moderate and scores between 8 and 12 were defined as high. ALDH1 is an original marker for early differentiation of stem cells and has never been assessed in a context of tubo-ovarian dysplasia: we propose a comprehensive description according to the cellular type (epithelium/stroma), cyctoplasmic/nuclear localization, and comparing morphologic dysplastic epithelium/normal epithelium. According to Chang *et al.,*^[@ref20]^ the degree of staining was quantified using a four-score grading system: cores with \<5% ALDH1- positive cells were scored as 0, those with 5-20% ALDH1-positive cells were scored as 1, those with 20-50% ALDH1-positive cells were scored as 2 and those with \>50% ALDH1-positive cells were scored as 3. For the statistical analysis, we divided cases into two groups as described by Chang *et al.:*^[@ref20]^ low expression (scores between 0 and 1) and high expression (scores between 2 and 3).

This study was approved by the institutional review boards at the Centre Jean Perrin.

Statistical analysis {#sec2-3}
--------------------

Our main measurement was the mean ovarian/tubal dysplasia score. Student's test was used to compare the dysplasia scores of the three groups. For evaluation of immunostains, non-parametric Wilcoxon statistics were applied.

Results {#sec1-3}
=======

The comparison was made between 42 removed ovaries and tubes associated with TAM, 15 cases from the clomiphen group and 116 normal salpingo-oophorectomies with respect to morphological and immunohisto-chemical criteria. The indication for adnexectomy was represented in 80% and 70% of cases by the discovery of a cyst at ultrasound (respectively for group A and group B). In the remaining cases, the adnexectomy was associated with hysterectomy for metrorrhagia and/or the discovery of a thickening of the endometrium. In group C, surgical indication was metrorrhagia and/or pelvic pain. There were only two ovarian cancers in group A and no endometrial cancer was present. The ovarian cysts were always benign in groups A and B. All the adnexectomies were performed between 4 and 7 years after the introduction of tamoxifen.

Morphological analysis {#sec2-4}
----------------------

### Ovarian abnormalities {#sec3-5}

The cytological and architectural abnormalities of the ovarian epithelium described by our score were always assessed in the ovarian tissue. The histopathological abnormalities in all groups are described in [Table 2](#table002){ref-type="table"}. In group A, the most frequent abnormalities were represented by inclusion cysts, psammoma, epithelial pseudostratification and stromal hyperplasia. In group B, the most frequent abnormalities were represented by epithelial pseudostratification, epithelial proliferation, surface papillomatosis, cellular pleiomorphism, inclusion cysts, deep epithelial invaginations, and stromal hyperplasia. In group C, we can note that there were 51.7% of inclusion cysts. Based on this data, a mean ovarian dysplasia score was determined for each of the three groups: 3.69 for group A, 6.5 for group B and 3.62 for the controls (no statistical difference between the three groups). Mean ovarian dysplasia score was significantly higher in the clomiphene group than in group A or in controls (P=0.009 ).

### Tubal abnormalities {#sec3-6}

Cytological and architectural abnormalities of the tubal epithelium were more frequent in group A and B compared with controls. The histopathological abnormalities in all groups are described in [Table 3](#table001){ref-type="table"}.

Mean tubal dysplasia score was significantly higher in the TAM group and clomiphene group than in controls (respectively 7.8 *vs* 3.5, P\<0.007; and 6.8 *vs* 3.5, P=0.008). No signs of salpingitis were detected in these women. Histopathological fallopian tube dysplastic changes were mainly seen in the secretory cells lining.

Immunohistochemical analysis {#sec2-5}
----------------------------

The expression patterns differed according to the immunohistochemical markers studied:

### Ovarian analysis {#sec3-7}

Ki67 and p53 were low and infrequent in dysplastic and non-dysplastic areas in groups A ([Figure 1 a](#fig001){ref-type="fig"},[d](#fig001){ref-type="fig"}) and [B](#fig001){ref-type="fig"} ([Figure 1 b](#fig001){ref-type="fig"},[e](#fig001){ref-type="fig"}) compared with group C ([Figure 1 c](#fig001){ref-type="fig"},[f](#fig001){ref-type="fig"}) (P=0.82). Positivity for these two markers was found predominantly in the inclusion cysts and invaginations relative to the ovarian surface epithelium.

### Tubal analysis {#sec3-8}

Expression of Ki67 and p53 appeared to be moderate in groups A ([Figure 2 a](#fig002){ref-type="fig"},[d](#fig002){ref-type="fig"}) and B ([Figure 2 b](#fig002){ref-type="fig"},[e](#fig002){ref-type="fig"}) in comparison with group C ([Figure 2 c](#fig002){ref-type="fig"},[f](#fig002){ref-type="fig"}) (P=0.0047).

### ALDH1 analysis {#sec3-9}

ALDH1 was highly expressed in the tube and ovary, in the presence of dysplasia. In non-dysplastic and in normal ovarian and tubal tissues in groups A and B, expression of ALDH1 was low and comparable to that in normal tissues of the control group ([Figure 1i](#fig001){ref-type="fig"} and [Figure 2i](#fig002){ref-type="fig"}). However, in morphologically dysplastic ovarian or tubal tissues, its expression was high and its localization was cytoplasmic. Immunohistologic fallopian tube dysplastic changes were mainly seen in the secretory cells lining. In stroma, high cytoplasmic and nuclear staining of ALDH1 was noted and thus constituted our internal control.

Noteworthy, ALDH1 expression was constantly low in the 2 carcinomas in group A (cytoplasmic staining) whereas p53 and Ki67 expression was high. Tamoxifen and clomid similarities and differences compared to the controls are shown in [Figure 1 g-i](#fig001){ref-type="fig"} and [Figure 2 g-i](#fig001){ref-type="fig"}, and summarized in [Table 4](#table001){ref-type="table"}.

Discussion {#sec1-4}
==========

Ovarian dysplasia was initially described in ovaries with a genetic risk of cancer.^[@ref4],[@ref5],[@ref21]^ By analogy with pre-invasive cervical lesions, the generic term *dysplasia* was proposed. The fact that these ovaries could evolve towards malignancy in absence of prophylactic ovariectomy led to the idea that ovarian epithelial dysplasia was the missing link prior to neoplasia. More recently, similar ovarian lesions described as dysplasia were detected in ovaries stimulated during *in vitro* fertilization (IVF) treatment. Nieto *et al.*^[@ref12]^ firstly found significant abnormalities in stimulated ovaries compared to a control population. Our previous studies confirmed these results (mean dysplasia score 7.64) and ovarian dysplasia seemed to be linked to the intensity and number of stimulations (dose-effect) and after a sufficient lapse of time (time-effect).^[@ref13]^ However, the long term evolution is unknown.^[@ref14],[@ref22]^ Animal experiments have given some interesting conclusions. Ovulation in rats resulted in dysplastic abnormalities in the ovarian epithelium with a relationship between the number of induced ovulation cycles and the severity of ovarian dysplasia.^[@ref23]^ Tamoxifen has a clomid-like effect and has sometimes been used in ovulation stimulation protocols.^[@ref1],[@ref2]^ In addition, the deleterious effects of tamoxifen on the endometrium, such as endometrial polyps, endometrial carcinoma and endometrial hyperplasia^[@ref27],[@ref28]^ are now well-known. However, results about the relationship between ovarian cancers and tamoxifen are contradictory: in some studies, tamoxifen treatment for breast cancer does not appear to increase the risk of ovarian cancer,^[@ref29],[@ref30]^ whereas other studies have indicated ovarian cancer arising with prolonged use of Tamoxifen.^[@ref31],[@ref32]^ We found few morphological ovarian abnormalities in TAM group whereas there were more abnormalities in ovaries associated with clomiphen; Madhavi *et al.*^[@ref22]^ proposed in his recent review a possible causal link between induction of ovulation and ovarian tumors because clomiphen appear to increase the risk of borderline ovarian tumors.

Results in tubal dysplasia associated with the administration of TAM or clomiphen are very interesting because of the similar profiles. It is true that the link between cause and effect is difficult to establish since these patients had all had breast cancer for which this hormone therapy was the final treatment. However, all the adnexectomies took place after at least four years of tamoxifen use; except for two patients excluded from the dysplasia scoring analysis, no patient had a BRCA 1 or 2 mutation and no patient had any other cancer with an epidemiological connection. The literature reports only two cases of bilateral atypical tubal hyperplasia in tamoxifentreated women.^[@ref33]^ Hyperplasia of the oviduct has also been described in female offspring of CD-1 mice that were prenatally exposed to tamoxifen.^[@ref34]^. An even more recent animal study found ovarian dysplasia in female rats given tamoxifen but the slight increase in dysplasia was not significant: the authors raised the question of a longer duration of Tamoxifen administration.^[@ref35]^ Another animal study found histopathological dysplasia in ovaries and tubes exposed to tamoxifen with a high Ki67 expression and a low p53 expression.^[@ref36]^ Moreover, these results raise the question of the pathogenesis of tubo-ovarian carcinogenesis. More recently, during systematic histopathological examination of tissues from prophylactic adnexectomies for a genetic risk, the revelation of occult tubal cancer (about 10%, and between 50 and nearly 100% of these cases have exhibited involvement of the fimbriated end of the fallopina tube) gave rise to the postulate of a tubal origin for ovarian cancer.^[@ref37],[@ref41]^ In view of these results, the combination of a systemic oestrogenic effect with the clomid-like effect of tamoxifen could be evoked on the epithelium of the tubes (such as in the ndometrium).^[@ref42]^

The immunohistochemical study added an extra-parameter for describing tubo-ovarian dysplasia. The two immunohistochemical markers p53 and Ki67 are described as being significantly expressed in ovarian cancer tissues compared with controls. The postulate that these markers would be expressed in dysplastic tissues could thus confirm their preinvasive nature. Schlosshauer *et al.*^[@ref19]^ found in their study a gradual increase in immunoreactivity comparing normal ovarian epithelium (lowest expression), dysplastic epithelium (stronger expression) and ovarian cancer (highest expression), which would represent a molecular argument for the existence of dysplasia. Concerning tubal dysplasia, Piek *et al.*^[@ref18]^ found distinct expression of these two markers in dysplastic tubes. In our study, expression of Ki67 and p53 appeared to be weak in ovaries whereas they were more marked in tubes of groups A and B: this could be another argument for the importance of tubes in the tuboovarian dysplasia pathogenesis. Histopathological and immunohistochemical fallopian tube dysplastic changes were mainly seen in the secretory cells lining, as they are the potential significant precursors of tubal and ovarian cancer. Last but not the least, the originality of our study also lies in the assessment of the marker for early stem cell differentiation, ALDH1. Several scientific proofs could support the cancer stem cell hypothesis for which some human cancers could originate in tissue stem and/or progenitor cells.^[@ref43]^ The true function of ALDH1 is not well known and could involve in early stem cell differentiation. The high ALDH1 expression in normal human and mouse ovary, its potential role in cancer stem cells in other tumors (especially breast cancer where it may be a predictor of poor clinical outcome) suggest that ALDH1 could have an implication in ovarian tumors. This enzyme is involved in the metabolism of retinoic acids, which plays an important role in regulation of pathways like AKT/β-cathénine, WNT, p21/p53.^[@ref44],[@ref48]^

Immunohistochemical staining of ALDH1 expression was analysed in 442 primary ovarian carcinoma.^[@ref20]^ Unlike the case for breast cancer, ALDH1 would be a favourable prognostic factor in ovarian carcinoma because high expression was significantly associated with early-stage disease (P=0.006). In another study, ALDH1 expression and enzyme activity were lower in malignant ovarian tumors.^[@ref48]^ ALDH1 expression was constantly low in the 2 carcinomas of our study. The expression of ALDH1 appears to be exclusively found and strongly expressed in dysplastic ovarian and tubal epithelia. ALDH1 may have a different function in ovarian cancer than it does in breast cancer, where it is usually overexpressed.^[@ref49]^ We found a similar expression of ALDH1 in a series of prophylactic ovariectomies for BRCA mutations (*unpublished results*). ALDH1 seems to have a on/off effect (overexpression in dysplasia area) and may be highly restricted to epithelial tubal dysplasia and could be help in their identification ([Figure 1c](#fig001){ref-type="fig"}). Auersperg *et al*.^[@ref52]^ recently compared the stem-cell profile of ovarian surface epithelium and fallopian tube with 5 stem-cell markers (NANOG, SFRP1, LHX9, ALDH1A1 and ALDH1A2). The authors found that ALDH1 was significantly increased in ovarian inclusion cysts and in the distal parts of the fallopian tube. They concluded that ovarian surface epithelium and tubal epithelium may have the capacity to undergo neoplastic transformation. Another study with different stem-cell markers (epithelial cell adhesion molecule, CD44, integrin a6) confirmed that stem cells are located in the distal end of the fallopian tubes.^[@ref53]^ However, the exact meaning and the mechanism of this strong expression remain to be investigated, and further studies are necessary.

Conclusions {#sec1-5}
===========

This morphological and immunohistochemical study found significant dysplastic epithelial lesions in a series of adnexectomy tissues in women exposed to tamoxifen. One of the possible clinicopathological explanations would be the combination of a systemic oestrogenic effect with the clomid-like effect of tamoxifen. However, the reason why the lesions are predominantly found in the tubes rather than in the ovaries remains questionable. This could point out the importance of the newly tubal theory of ovarian carcinogenesis. There are many elements of bias that could make the involvement of tamoxifen in the genesis of the dysplasia debatable. However, these results could encourage a fully comprehensive pathological analysis of adnexectomy tissues to be carried out for all patients with tamoxifen exposure.^[@ref54]^

![Ki67, p53 and ALDH1 immunoreactivity in ovary; left column, after treating with tamoxifen; center column, after treating with clomid; right column, untreated control group. a-c) Immunoreactivity for Ki67; note the absence of Ki67 expression in all the three representative groups. d-f) Immunoreactivity for p53; p53 expression is low in the ovarian epithelium exposed to tamoxifen; in contrast, there is no p53 expression in ovary exposed to clomid and in the control group. g-i) immunoreactivity for ALDH1; the expression of ALDH1 is strong in ovaries exposed to tamoxifen and clomid, whereas no immunopositivity for ALDH1 was observed in the control group; intense staining for ALDH1 was noted in stroma (internal control). Scale bars: 100 µm.](ejh-2014-2-2251-g001){#fig001}

![Ki67, p53 and ALDH1 immunoreactivity in fallopian tube; left column, after treating with tamoxifen; center column, after treating with clomid; right column, untreated control group. a-c) Immunoreactivity for Ki67; note the moderate expression of Ki67 in the tubes exposed to tamoxifen and clomid, and the low expression in the control group. d-f) Immunoreactivity for p53; the expression of p53 is weak in the tubes exposed to tamoxifen and clomid, and not present in the control group. g-h) ALDH1 immunoreactivity; note the strong expression of ALDH1 in the tubes exposed to tamoxifen and clomid, and the low or absent expression in the control group; also note the on/off effect of ALDH1 expression in panel h, where ALDH1 is mainly detected in the secretory cells lining but not in the ciliated cells. Scale bars: 100 µm.](ejh-2014-2-2251-g002){#fig002}

###### 

Immunohistochemical characteristics.

  Antibody   Clone     Manufacturer     Dilution   Incubation   Detection
  ---------- --------- ---------------- ---------- ------------ -----------
  Ki67       MIB-1     DAKO             1/100      32 min       Ultraview
  P53        DO-7      DAKO             1/200      32 min       Ultraview
  ALDH1      44/ALDH   BD Biosciences   1/400      60 min       Ultraview

###### 

Comparison of respective frequencies of the eleven histopathologic abnormalities in our ovarian dysplasia scoring system.

  --------------------------------------------------------------------------------------------
  Histopathological items                Group A\     Group B\     Group C\     P
                                         (n= 40)      (n=15)       (n=116)      
  -------------------------------------- ------------ ------------ ------------ --------------
  Epithelial pseudostratification        23 (57.5%)   10 (66.6%)   54 (46.5%)   P1=0.240\
                                                                                P2=0.032\
                                                                                P3=0.750

  Epithelial proliferation               12 (30%)     11 (73.3%)   35 (30.1%)   P1=0.930\
                                                                                P2=0.002\
                                                                                P3=0.003

  Surface papillomatosis                 14 (35%)     9 (60%)      27 (23.2%)   P1=0.1200\
                                                                                P2=0.0070\
                                                                                P3=0.0074

  Irregular nuclear chromatine pattern   13 (32.5%)   7 (46.6%)    21 (18.1%)   P1=0.054\
                                                                                P2=0.0072\
                                                                                P3=0.07

  Irregular nuclear contour              7 (17.5%)    7 (46.6%)    35 (30.1%)   P1=0.371\
                                                                                P2=0.060\
                                                                                P3=0.0071

  Cellular pleiomorphism                 13 (32.5%)   8 (53.3%)    36 (31%)     P1=0.515\
                                                                                P2=0.006\
                                                                                P3=0.007

  Increase in nuclear size               5 (12.5%)    7 (46.6%)    22 (18.9%)   P1=0.5130\
                                                                                P2=0.0038\
                                                                                P3=0.0025

  Inclusion cysts                        24 (60%)     10 (66.6%)   60 (51.7%)   P1=0.196\
                                                                                P2=0.12\
                                                                                P3=0.82

  Deep epithelial invaginations          17 (42.5%)   13 (86.6%)   42 (36.2%)   P1=0.324\
                                                                                P2=0.012\
                                                                                P3=0.019

  Psammoma                               22 (55%)     6 (40%)      13 (11.2%)   P1\<0.001\
                                                                                P2=0.0052\
                                                                                P3=0.74

  Stromal hyperplasia                    28 (70%)     13 (86.6%)   29 (25%)     P1\<0.0001\
                                                                                P2\<0.00001\
                                                                                P3=0.24
  --------------------------------------------------------------------------------------------

P1, statistical differences between group A and C; P2, statistical differences between group B and C; P3, statistical differences between group A and B.

###### 

Comparison of respective frequencies of the seven histopathologic abnormalities in our tubal dysplasia scoring system.

  --------------------------------------------------------------------------------------
  Histopathological items           Group A\     Group B\     Group C\     P
                                    (n= 40)      (n=15)       (n=116)      
  --------------------------------- ------------ ------------ ------------ -------------
  Epithelial pseudostratification   36 (90%)     13 (86.6%)   56 (48.2%)   P1=0.0001\
                                                                           P2=0.0002\
                                                                           P3=0.82

  Tufting                           32 (80%)     13 (86.6%)   13 (11.2%)   P1\<0.0001\
                                                                           P2\<0.0001\
                                                                           P3=0.9100

  Loss of nuclear polarity          36 (90%)     12 (80%)     26 (22.4%)   P1\<0.0001\
                                                                           P2=0.003\
                                                                           P3=0.76

  Increase in nuclear density       35 (87.5%)   7 (46.6%)    14 (12%)     P1\<0.0001\
                                                                           P2=0.0015\
                                                                           P3=0.011

  Nuclear atypia                    20 (50%)     12 (80%)     11 (9.4%)    P1\<0.0001\
                                                                           P2\<0.0001\
                                                                           P3=0.021

  Nucleomegaly                      34 (85%)     10 (66.6%)   14 (12%)     P1\<0.0001\
                                                                           P2\<0.0001\
                                                                           P3=0.12

  Loss of ciliation                 34 (85%)     12 (80%)     7 (6%)       P1\<0.0001\
                                                                           P2\<0.0001\
                                                                           P3=0.89
  --------------------------------------------------------------------------------------

P1, statistical differences between group A and C; P2, statistical differences between group B and C; P3, statistical differences between group A and B.

###### 

Tamoxifen and clomid similarities and differences.

                              Group A: TAM   Group B: Clomid   Group C: Control
  --------------------------- -------------- ----------------- ------------------
  Ovarian dysplasia score     3.69           6.5               3.62
  Ovarian Ki67 expression     Low            Low               Low
  Ovarian p53 expression      Low            Low               Low
  Ovarian ALDH 1 expression   High           High              Low
  Tubal dysplasia score       7.8            6.8               3.5
  Tubal Ki67 expression       Moderate       Moderate          Low
  Tubal p53 expression        Moderate       Moderate          Low
  Tubal ALDH1 expression      High           High              Low

TAM, tamoxifen.
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